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Abstract
Background: Action myoclonus-renal failure syndrome is a hereditary form of progressive myoclonus epilepsy
associated with renal failure. It is considered to be an autosomal-recessive disease related to loss-of-function
mutations in SCARB2. We studied a German AMRF family, additionally showing signs of demyelinating
polyneuropathy and dilated cardiomyopathy.
To test the hypothesis whether isolated appearance of individual AMRF syndrome features could be related to
heterozygote SCARB2 mutations, we screened for SCARB2 mutations in unrelated patients showing isolated AMRF
features.
Methods: In the AMRF family all exons of SCARB2 were analyzed by Sanger sequencing. The mutation screening of
unrelated patients with isolated AMRF features affected by either epilepsy (n = 103, progressive myoclonus
epilepsy or generalized epilepsy), demyelinating polyneuropathy (n = 103), renal failure (n = 192) or dilated
cardiomyopathy (n = 85) was performed as high resolution melting curve analysis of the SCARB2 exons.
Results: A novel homozygous 1 bp deletion (c.111delC) in SCARB2 was found by sequencing three affected
homozygous siblings of the affected family. A heterozygous sister showed generalized seizures and reduction of
nerve conduction velocity in her legs. No mutations were found in the epilepsy, renal failure or dilated
cardiomyopathy samples. In the polyneuropathy sample two individuals with demyelinating disease were found to
be carriers of a SCARB2 frameshift mutation (c.666delCCTTA).
Conclusions: Our findings indicate that demyelinating polyneuropathy and dilated cardiomyopathy are part of the
action myoclonus-renal failure syndrome. Moreover, they raise the possibility that in rare cases heterozygous
SCARB2 mutations may be associated with PNP features.
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Action myoclonus-renal failure syndrome (AMRF,
OMIM 254900) is characterized by neurological symp-
toms such as progressive action myoclonus epilepsy
(PME), dysarthria, ataxia, and generalized seizures. In
addition, patients develop end-stage renal failure (RF)
requiring dialysis and/or renal transplantation [1-4]. The
syndrome is considered to be an autosomal-recessive dis-
ease related to loss-of-function mutations in SCARB2
which encode a lysosomal-membrane type 2 protein, a
member of the CD 36 scavenger receptor-like protein
family [5,6]. b-glucocerebrosidase (b-GC) trafficking
requires SCARB2 protein binding for transfer from the
endoplasmatic reticulum to the lysosome [6,7]. Scarb2
-/-
mice have hydronephrosis, deficiency in glomerular filtra-
tion and peripheral demyelinating neuropathy but no epi-
leptic sign [8]. They show normal cardiac development,
but fail to show a hypertrophic response to increased
blood pressure and develop dilated cardiomyopathy [9].
We examined an AMRF family with three affected sib-
lings showing typical features [2]. Epileptic seizures and
a loss of sensation in the feet occurred in one sister.
Methods
AMRF Family
We sequenced the SCARB2 gene in a previously described
AMRF family [2,4]. Three of six children had AMRF and
developed PME and renal failure within the first two dec-
ades of life. In addition to common AMRF features, all
affected siblings also had demyelinating polyneuropathy
(PNP). PNP was diagnosed before the patients developed
renal failure [4]. For detection of peripheral neuropathy,
electromyography (EMG) and nerve conduction studies
(NCS) and/or skin punch biopsy were performed. In two
siblings echocardiography revealed dilated cardiomyopathy
(DCM) at the ages of 14 and 21. A sister of the affecteds
had generalized seizures beginning at the age of 14 and a
clinically diagnosed reduction of nerve conduction velocity
in her legs.
Patient Populations
We screened the following patient samples for muta-
tions in SCARB2:
Epilepsy patients with PME or generalized epilepsy
(GE): 28 unrelated German PME patients and 75 unre-
lated Austrian epilepsy patients. The German patients
derived from a sample of 30 PME patients resembling
Unverricht-Lundborg disease (nine females, 21 males,
mean age: 26.8 ± 14.3 years) from which two were
excluded since they were found to be siblings who had
compound heterozygote CSTB mutations. The Austrian
sample (40 female, 35 male, mean age: 29.3 years, range
18-68 years) was composed of three PME patients, seven
juvenile epilepsy syndrome patients and 65 GE patients.
Renal failure: 192 unrelated German dialysis patients
(76 female, 116 male, mean age: 66 ± 10.3 years).
Cardiomyopathy: 85 unrelated German patients with
DCM (14 female, 71 male, mean age: 55 ± 13.2 years).
Polyneuropathy: 103 unrelated German patients with a
clinical diagnosis of PNP (32 female, 71 male, mean age:
58 ± 13.5 years).
Sequencing
Genomic DNA was extracted from peripheral blood using
standard procedures for sequencing of 12 SCARB2 exons
and 11 beta-glucosidase (GBA) exons, including the exon/
intron boundaries. BigDye terminator chemistry 3.1 (ABI)
and an ABI3730 sequencer were used. Primers were
designed by Exon Primer [10] respectively Primer3plus
[11] software. For sequence analysis the Staden software
package was applied.
RT-PCR
All 12 SCARB2 exons were screened for deletions and
duplications by real-time polymerase chain reaction (RT-
PCR) in all members of the AMRF family and in PNP
patients using an ABI7900HT system and a SYBR Green I
detection dye. Gene dosage was determined using the
ΔCT method. To control variation of DNA concentration
and PCR efficiency BNC1 was used as a reference gene.
T h em e a ng e n ed o s a g eo fah e a l t h yc o n t r o lw a su s e df o r
calibration. All samples were taken in duplicates.
SCARB2 Mutation Screening
For mutation screening in the selected patient population,
i.e. epilepsy patients, renal failure patients, cardiomayopa-
thy patients and polyneuropathy patients high resolution
melting curve analysis of amplicons, spanning the 12
exons and splice junctions of SCARB2, was performed.
P C Rw a sr u ni na5μl reaction mixture containing:
Thermo Scientific High Performance Buffer with the con-
centration 1x, 2.5 mM MgCl2, 0.2 mM dNTPs, 0.05 U/μl
Taq DNA Polymerase, Primer 0.4 μM each, DNA-binding
dye LC-Green-Plus (Idaho Technology Inc., Salt Lake
City, UT) with the concentration 0.5x, 2.8 μlH 2OHPLC and
8 ng of genomic DNA.
To facilitate heteroduplex formation and in order to
detect homozygous variants, reactions were spiked with
wild type genomic DNA (1: 20 titration). The mixture was
covered with a mineral oil overlay to prevent evaporation
during heating on the LightScanner. Melting data were
analysed using the LightScanner Software Call-IT v1.1
(Idaho Technology). The presence of a mutation was
revealed by an aberrant melting curve. Samples flagged as
potential variants were subjected to DNA sequencing.
All experimental research was done in compliance with
the Helsinki Declaration. This research was conducted ret-
rospectively therefore yielding minimum consequences to
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and the confidentiality of their personal information to
minimize the impact of the study on their physical, mental
and social integrity.
Results
Gene analysis of the AMRF family
In the patients II:1, II:3 and II:6 (Figure 1, Table 1, Table 2)
we identified a homozygous 1 bp-deletion (c.111delC) in
exon1 (Figure 2) resulting in frameshift and premature
stop after 17 bp. In patients I:1, I:2, we identified the same
deletion as being heterozygous and in patient II:4 we could
not detect any mutation. There is no information available
about genotype status of patient II:2. Patient II:5 carried
the same deletion in a heterozygous state. Sequencing of
GBA in all family members did not reveal any mutation in
any member of this family.
Screening for SCARB2 mutations in GE, RF, and DCM
patient population
SCARB2 high resolution melting analysis of the GE, RF,
and DCM patients did not reveal any case of apparent
mutation.
Screening for SCARB2 mutations in PNP patient
population
The 103 unrelated German PNP patients have been diag-
nosed by clinical investigation as well as standardized
quantitative sensory testing (QST). Among the 103 PNP
patients we identified two individuals carrying a heterozy-
gous frameshift mutation in an exonic region of SCARB2,
i.e. c.666delCCTTA respectively p.Y222XfsX in exon5
(Figure 3). This mutation has been described before in a
patient with PME [12]. Neither this mutation nor the
mutation detected in the AMRF family were found in
1452 normal chromosomes of the general population indi-
cating that these are rare variants with a frequency below
0.1%. Controls were of European descent and were
recruited from the KORA S3/F3 and S4 surveys, i.e. from
the general population living in or near the city of Augs-
burg, Germany. KORA procedures and samples have been
described previously [13].
Discussion
The phenotype of the action myoclonus-renal failure syn-
drome (AMRF) is variable [2]. Some patients do not
show evidence of the classic combination of epilepsy and
renal failure. Homozygous and compound heterozygous
mutations of SCARB2 have been identified in patients
who had only progressive myoclonus epilepsy (PME) but
no renal failure (RF) [12]. On the other hand, the spec-
trum of features may possibly be more extended than
currently assumed. Here, we report an AMRF family with
a novel 1 bp deletion (c.111delC). Of the three affected
homozygotes in this family, two had cardiomyopathy
(DCM) and all three had demyelinating polyneuropathy
(PNP) already before the onset of renal failure. Our find-
ings suggest that DCM and PNP are facultative features
of the AMRF phenotype. The detection of PNP in AMRF
syndrome is in keeping with observations on scarb2
-/-
mice where SCARB2-deficiency was found to be asso-
ciated with upregulation of lysosomal enzymes. This is
concomitant with a downregulation of peripheral myelin
proteins, accumulation of abnormal inclusions in the
outer cytoplasmic zone of Schwann cells, massive loss of
peripheral myelin proteins, onion bulbs and other myelin
abnormalities, and secondary axonal degeneration,
restricted to the peripheral nervous system [8].
A 27-year-old, heterozygous sibling of patients II:1, II:2,
II:3, II:4, II:6 had generalized seizures beginning at the
age of 14. She also additionally exhibited a reduction of
nerve conduction velocity. However, the heterozygous
mutation was associated with a detectable AMRF feature
only in this sibling, whereas the other heterozygotes in
the family (parents, other sister) were by history asymp-
tomatic. This observation suggested that the potential
association cannot be strong. To exclude a synergistic
effect of two compound heterozygous mutations in the
same lysosomal pathway, we additionally sequenced the
11 beta-glucosidase (GBA)e x o n s .N oGBA mutation was
found. The phenotypical effect of heterozygous SCARB2
mutations has been discussed before in the case of a
patient with myoclonus epilepsy and isolated proteinuria
[14]. Moreover, earlier studies on families affected by
myoclonus epilepsy of Unverricht and Lundborg (EPM1;
CSTB mutations; OMIM 254800) reported mild symp-
toms in heterozygous carriers of the disease allele [15,16].
In keeping with the latter observation, features of the
EPM1 phenotype were described in cstb
+/- mice [17].
Similarly, screening of scarb2
+/- mice for AMRF features
may help to elucidate the impact of heterozygous
SCARB2 mutations.
Figure 1 Pedigree of the AMRF family with mutation status.
Black symbol: AMRF. Grey symbol: generalized epilepsy and
reduction of nerve conduction velocity in the feet. +/+:
homozygous mutation, +/-: heterozygous mutation. Symbol #: no
information available about genotype status.
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Page 3 of 8Table 1 Onset of neurological features [yrs] in members of the AMRF pedigree depicted in Figure 1 and Figure 2
patient [pedigree number] sex age of onset action myoclonus tonic clonic seizures ataxia demyelinating polyneuropathy hearing impairment age at death [yrs]
II:1 m 14 14 20 14 + NA 31
II:6 f 20 20 20 20 + 26 34
II:3 m 20 26 32 20 + NA 38
II:5 f 14 - 14 - unclear - alive
If known, the age of onset [yrs] of a feature is indicated; “+” = present but age of onset unknown; “-” = absent; “NA” = not assessed.
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8Table 2 Onset of renal and cardiovascular features [yrs] in members of the AMRF pedigree depicted in Figure 1 and Figure 2
patient [pedigree number] sex age of onset dialysis renal trans-plan-tation dilated cardio-myopathy hypertension age at death [yrs]
II:1 m 14 18 - < 14 + 31
II:6 f 20 22 - < 21 + 34
II:3 m 20 26 31 - + 38
II:5 f 14 - - - + alive
If known, the age of onset [yrs] of a feature is indicated; “+” = present but age of onset unknown; “-” = absent; “NA” = not assessed.
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8Figure 2 SCARB2 sequence in the AMRF family. Top row, homozygous c.111delC mutation of patient II:3. Middle row, sequence of
heterozygous carrier II:5. Bottom row, wild type sequence.
Figure 3 SCARB2 sequence in a PNP patient. Top row, heterozygous mutation c.666delCCTTA. Bottom row, wild type sequence.
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Page 6 of 8Therefore, we examined the possibility that the fre-
quency of SCARB2 mutations may be increased in
patients with isolated features of AMRF. To further
examine the possible relationship between heterozygous
mutations in SCARB2 and isolated AMRF signs such as
generalized epilepsy (GE) (n = 75), progressive action
myoclonus epilepsy (PME) (n = 28), renal failure (RF) (n
= 192), polyneuropathy (PNP) (n = 103), and dilated car-
diomyopathy (DCM) (n = 85), respective patient samples
were scrutinized for putative mutations. We identified
two heterozygous PNP patients carrying the SCARB2
mutation p.Y222XfsX located within the highly con-
served b-GC binding domain [7]. Before, this frameshift
mutation has been identified as being homozygous in a
PME patient [12]. In the 103 PNP patients electrophysio-
logical data on the nerve conduction study is not avail-
able. However, histopathological analysis of a nerve
biopsy taken from one of the two patients carrying the
p.Y222XfsX mutation showed evidence of demyelinating
PNP. We have not performed any mutational screening
of our DCM patients in sarcomeric proteins. None of the
other monosymptomatic patients had a SCARB2 muta-
tion. Thus, our findings are not in line with a recent
report of high frequency of homozygous or compound
heterozygote SCARB2 mutations in patients with isolated
PME (clinically resembling Unverricht-Lundborg disease
but being negative for CSTB mutations) [12]. However,
the frequency of SCARB2 mutations in PME patients
may differ between different populations.
Note added in proof: A recent report on a patient with
PME and a demyelinating neuropathy affirmed our finding
that polyneuropathy belongs to phenotype spectrum of
SCARB2 mutation [18,19].
Conclusions
We conclude that SCARB2 mutations may possibly contri-
bute to the genesis of isolated AMRF-like features in rare
cases, but do not appear to be a major cause of these fea-
tures in the general population. To assess these findings
further populations with PNP would have to be examined
to see how frequently heterozygote SCARB2 mutations
can explain a PNP.
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